BOOK
Molecular Imaging and Precision Medicine, Part II, An Issue of PET Clinics, E-Book
(2017)
Additional Information
Book Details
Abstract
This issue of PET Clinics focuses on Molecular Imaging and Precision Medicine, Part II, and is edited by Dr. Rathan Subramaniam. Articles will include: Precision Medicine in Esophageal Cancer; Precision Medicine and PET/CT in Melanoma; Precision Medicine and PET/CT in Hepatobilliary and Pancreatic Cancer; Precision Medicine and PET/CT in Gastric Cancer; Precision Medicine and PET/CT in Skeletal and Soft Tissue Sarcomas; Precision Medicine and PET/MRI; Precision Medicine and PET/CT in Uterine and Ovarian Cancers; Precision Medicine and PET/CT in Cardiovascular Disorders, and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Molecular Imaging and Precision Medicine, Part II\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface: Precision Medicine and PET/Computed Tomography: Emerging Themes for Future Clinical Practice | v | ||
| PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer 373 | v | ||
| Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers | v | ||
| PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors | v | ||
| Precision Medicine and PET–Computed Tomography in Pediatric Malignancies | v | ||
| PET/Computed Tomography and Precision Medicine: Gastric Cancer | vi | ||
| Precision Medicine and PET/Computed Tomography in Melanoma | vi | ||
| Precision Medicine and PET/Computed Tomography in Cardiovascular Disorders | vi | ||
| PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma | vi | ||
| The Role of PET/MR Imaging in Precision Medicine | vii | ||
| PET CLINICS\r | viii | ||
| FORTHCOMING ISSUES | viii | ||
| January 2018 | viii | ||
| April 2018 | viii | ||
| July 2018 | viii | ||
| RECENT ISSUES | viii | ||
| July 2017 | viii | ||
| April 2017 | viii | ||
| January 2017 | viii | ||
| CME Accreditation Page | ix | ||
| PROGRAM OBJECTIVE | ix | ||
| TARGET AUDIENCE | ix | ||
| Preface:\rPrecision Medicine and PET/Computed Tomography: Emerging Themes for Future Clinical Practice | xi | ||
| REFERENCE | xii | ||
| PET/Computed Tomography Scanning and Precision Medicine | 373 | ||
| Key points | 373 | ||
| INTRODUCTION | 373 | ||
| GENOMICS | 374 | ||
| Squamous Cell Carcinoma | 374 | ||
| Adenocarcinoma | 374 | ||
| Somatic genomic alterations | 374 | ||
| Alterations in microRNA expression | 376 | ||
| STAGING AND PET/COMPUTED TOMOGRAPHY SCANNING | 377 | ||
| PRETHERAPY PET WITH FLUORINE-18 FLUORO-2-DEOXY-D-GLUCOSE/COMPUTED TOMOGRAPHY SCANNING AND PROGNOSIS | 380 | ||
| RESPONSE EVALUATION | 382 | ||
| PET WITH FLUORINE-18 FLUORO-2-DEOXY-D-GLUCOSE/COMPUTED TOMOGRAPHY SCANNING FOR RESPONSE EVALUATION DURING TREATMENT | 382 | ||
| PET WITH FLUORINE-18 FLUORO-2-DEOXY-D-GLUCOSE/COMPUTED TOMOGRAPHY SCANNING FOR RESPONSE EVALUATION AFTER TREATMENT | 383 | ||
| PET WITH FLUORINE-18 FLUORO-2-DEOXY-D-GLUCOSE/COMPUTED TOMOGRAPHY SCANNING FOR RECURRENCE DETECTION AND FOLLOW-UP | 383 | ||
| NOVEL TRACERS | 384 | ||
| NOVEL PET METRICS: TEXTURAL ANALYSIS | 385 | ||
| SUMMARY | 385 | ||
| REFERENCES | 386 | ||
| Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers | 393 | ||
| Key points | 393 | ||
| INTRODUCTION: PRECISION MEDICINE AND GYNECOLOGIC CANCER | 393 | ||
| PET SCANS IN THE INITIAL TREATMENT STRATEGY OF GYNECOLOGIC MALIGNANCY | 394 | ||
| Initial Staging | 394 | ||
| Endometrial cancer | 394 | ||
| Cervical cancer | 398 | ||
| Ovarian cancer | 399 | ||
| PET at Initial Diagnosis and Staging as a Biomarker of Prognosis | 400 | ||
| Prognostic value of various PET signatures in the primary lesion | 400 | ||
| Prognostic value of 18F-labeled 2-fluoro-2-deoxy-d-glucose avidity, extent of lymphadenopathy, and disease spread on PET | 400 | ||
| PET IN THE SUBSEQUENT TREATMENT STRATEGY OF GYNECOLOGIC MALIGNANCY | 401 | ||
| Detection of Recurrent Disease and Restaging | 401 | ||
| Endometrial cancer | 401 | ||
| Cervical cancer | 401 | ||
| Ovarian cancer | 401 | ||
| Midtherapy and Posttherapy PET for Monitoring Treatment Response and as a Predictive Biomarker of Outcome | 401 | ||
| SUMMARY | 402 | ||
| REFERENCES | 402 | ||
| PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors | 407 | ||
| Key points | 407 | ||
| PANCREATIC DUCTAL ADENOCARCINOMA | 408 | ||
| Introduction | 408 | ||
| Molecular Genetics | 408 | ||
| Epidermal growth factor receptor signaling | 408 | ||
| Vascular endothelial growth factor signaling | 409 | ||
| K-Ras signaling | 410 | ||
| 18F-Fluorodeoxyglucose PET–Computed Tomography in Diagnosis and Staging of Pancreatic Adenocarcinoma | 410 | ||
| Prognostic Value of 18F-Fluorodeoxyglucose PET–Computed Tomography in Pancreatic Adenocarcinoma | 411 | ||
| Role of PET–Computed Tomography Assessing Residual Disease and Recurrence in Pancreatic Adenocarcinoma | 413 | ||
| Novel PET–Computed Tomography Tracer in Pancreatic Adenocarcinoma | 414 | ||
| Imaging of cell proliferation: 18F-fluorothymidine PET–computed tomography | 414 | ||
| Textural Analysis | 414 | ||
| PANCREATIC NEUROENDOCRINE TUMORS | 415 | ||
| Diagnostic Studies | 415 | ||
| Peptide Receptor Radioligand Therapy | 416 | ||
| SUMMARY | 417 | ||
| REFERENCES | 417 | ||
| Precision Medicine and PET–Computed Tomography in Pediatric Malignancies | 423 | ||
| Key points | 423 | ||
| INTRODUCTION | 423 | ||
| PEDIATRIC BONE AND SOFT TISSUE SARCOMAS | 424 | ||
| LYMPHOMAS | 426 | ||
| Initial Staging | 426 | ||
| Therapy Response | 427 | ||
| NEUROBLASTOMA | 429 | ||
| WILMS TUMOR | 431 | ||
| PET/MR IMAGING | 431 | ||
| REFERENCES | 432 | ||
| PET/Computed Tomography and Precision Medicine | 437 | ||
| Key points | 437 | ||
| INTRODUCTION | 437 | ||
| DIAGNOSIS AND STAGING OF GASTRIC CANCER | 438 | ||
| EVALUATION OF THE PRIMARY TUMOR | 439 | ||
| EVALUATION OF LYMPH NODE AND DISTANT METASTASIS | 442 | ||
| DETECTION OF SYNCHRONOUS PRIMARY CANCERS | 443 | ||
| EVALUATION OF TREATMENT RESPONSE | 443 | ||
| DETECTION OF DISEASE RECURRENCE AND FOLLOW-UP | 443 | ||
| PREDICTION OF PROGNOSIS | 444 | ||
| SUMMARY | 445 | ||
| REFERENCES | 445 | ||
| Precision Medicine and PET/Computed Tomography in Melanoma | 449 | ||
| Key points | 449 | ||
| INTRODUCTION | 449 | ||
| MOLECULAR GENETICS AND IMMUNOMODULATION IN MELANOMA | 450 | ||
| PET IMAGING IN ASSESSING RESPONSE TO THERAPY IN THE ERA OF PERSONALIZED TREATMENT | 453 | ||
| PET AS A PREDICTIVE BIOMARKER OF PROGNOSIS IN THE NEW-GENERATION THERAPIES | 456 | ||
| SUMMARY/DISCUSSION | 457 | ||
| REFERENCES | 457 | ||
| Precision Medicine and PET/Computed Tomography in Cardiovascular Disorders | 459 | ||
| Key points | 459 | ||
| INTRODUCTION | 459 | ||
| NORMAL ANATOMY AND IMAGING TECHNIQUE | 460 | ||
| Normal Cardiac Anatomy | 460 | ||
| Cardiac Imaging Techniques | 460 | ||
| Normal Vascular Anatomy (Noncoronary) | 460 | ||
| Vascular Imaging Techniques | 460 | ||
| IMAGING PROTOCOLS | 460 | ||
| Myocardial Perfusion | 460 | ||
| Cardiac Viability | 460 | ||
| Cardiac Sarcoidosis | 461 | ||
| Cardiac Amyloidosis | 461 | ||
| Cardiovascular Infection, Inflammation, and Neoplasm | 461 | ||
| IMAGING FINDINGS/PATHOLOGY | 462 | ||
| Cardiac/Pericardiac Imaging | 462 | ||
| Perfusion | 462 | ||
| Viability | 462 | ||
| Nonischemic cardiomyopathies and inflammatory disorders | 462 | ||
| Sarcoidosis | 462 | ||
| Nonischemic inflammatory cardiomyopathies | 462 | ||
| Amyloidosis | 462 | ||
| Neoplasm | 462 | ||
| PET/Computed Tomography and Precision Medicine | 475 | ||
| Key points | 475 | ||
| INTRODUCTION | 475 | ||
| MOLECULAR GENETICS | 476 | ||
| Soft Tissue Sarcomas | 476 | ||
| Diagnosis and grading | 476 | ||
| Staging | 477 | ||
| Prognostication | 478 | ||
| Therapy monitoring | 478 | ||
| Tumor recurrence | 479 | ||
| Gastrointestinal Stromal Tumors | 479 | ||
| Skeletal Sarcoma | 480 | ||
| Osteosarcoma | 481 | ||
| Diagnosis and staging | 481 | ||
| Therapy monitoring | 482 | ||
| The Role of PET/MR Imaging in Precision Medicine | 489 | ||
| Key points | 489 | ||
| INTRODUCTION | 489 | ||
| PET/MR IMAGING VERSUS PET/COMPUTED TOMOGRAPHY | 490 | ||
| PRECISION MEDICINE | 491 | ||
| POTENTIAL OF HYPERPOLARIZED MR IMAGING | 491 | ||
| NONTARGETED MOLECULAR PROBES | 491 | ||
| TARGETED MOLECULAR IMAGING | 494 | ||
| Prostate Carcinoma | 494 | ||
| NEUROENDOCRINE TUMORS | 496 | ||
| SUMMARY | 497 | ||
| REFERENCES | 498 |